Our findings suggest that the co‐administration of ABCA and Anti‐PD1 leads to a reduction in TGF‐β levels in tumor tissues compared to treatment with Anti‐PD1 alone, indicating a potential decrease of the immunosuppressive microenvironment with the combined therapy. Here, TGFB1 is linked to neoplasm.